Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision
2025 年 10 月 4 日
Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) is considered one of the best stocks to buy under $20.
On September 19, Syndax Pharmaceuticals announced a major milestone: the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia (AML) to include Revuforj (revumenib).
Revuforj received a Category 2A recommendation for the treatment of relapsed […]
https://ca.finance.yahoo.com/news/syndax-revumenib-added-nccn-aml-205447064.html